Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC)

NCT06585410 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT06585410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06585410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC)
Lead sponsor
Regeneron Pharmaceuticals
Phase
Phase 3
Overall status
Recruiting
Start date
January 2, 2025
Completion date
May 3, 2030
Enrollment
369 (estimated)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous squamous cell carcinoma (cscc)